Search Results

Press Releases

In-Vitro Diagnostics Enzymes Market Size to Surpass USD 4.10 Bn by 2033

November 19, 2024

·

1 min read

NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

NextCure, Inc. today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

May 30, 2024

·

5 min read

Drug Development

Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy

Ocugen, Inc. announced a positive outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa clinical trial for OCU410 —a modifier gene therapy candidate being developed for geographic atrophy, an advanced stage of dry age-related macular degeneration.

May 31, 2024

·

5 min read

Press Releases

Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

October 23, 2024

·

5 min read

Press Releases

Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

November 19, 2024

·

5 min read

Pharm Country

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease

Ocugen, Inc. announced that the Data Safety and Monitoring Board for the OCU410ST clinical trial recently convened and approved to proceed dosing with the medium dose of OCU410ST in the dose-escalation phase of the study.

April 1, 2024

·

4 min read

Drug Development

Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy

Ocugen, Inc. today announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV- hRORA ).

April 19, 2024

·

5 min read

Press Releases

Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease

November 20, 2024

·

5 min read

Drug Development

Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy

Ocugen, Inc. announced that the Data and Safety Monitoring Board for the Phase 1/2 ArMaDa clinical trial for OCU410 recently convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.

April 5, 2024

·

4 min read

Drug Development

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST —a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life.

May 15, 2024

·

5 min read